Approval

Gazyva Wins Kidney Disease Approval

The FDA approved Roche's Gazyva for adults with primary membranous nephropathy at risk of progression, making it the first FDA-approved treatment for the disease. In the phase 3 MAJESTY trial, complete remission of proteinuria at two years occurred in 36.1% of patients receiving Gazyva versus 5.7% receiving tacrolimus. Roche reported no new safety signals and said regulators are also considering Gazyva for systemic lupus erythematosus.

Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call